All In Biotech

Drug Trial Radar · NCT07022002

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

A Phase II Study to Evaluate the Safety and Efficacy of SSGJ-705 Monotherapy and Combination Therapy in Patients With Advanced HER2-Expressing Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

340

Planned (sponsor's estimate)

Start

Jul 30, 2025

Primary completion

Dec 31, 2026

Study completion Dec 12, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.

Conditions

  • Locally Advanced, Recurrent or Metastatic Malignancies

Interventions

  • SSGJ-705Drug

    anti-PD-1 (programmed cell death protein 1) and anti-HER2 (Human Epidermal GrowthFactor Receptor 2)bispecifc antibody

  • PD-1/L1 inhibitor combined with chemotherapyDrug

    Immune checkpoint inhibitors

  • SSGJ-705 combined with chemotherapyDrug

    anti-PD-1 and anti-HER2 bispecifc antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: 12 months
  2. Incidence of Treatment-Emergent Adverse EventsTime frame: 12 months
  3. Severity of Treatment-Emergent Adverse EventsTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.